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Abstract The Ca2+-independent acceleration of dephosphoryla-
tion of the regulatory light chain of smooth muscle myosin and
relaxation of smooth muscle by telokin are enhanced by cyclic
nucleotide-activated protein kinase(s) [Wu et al. (1998) J. Biol.
Chem. 273, 11362^11369]. The purpose of this study was to
determine the in vivo site(s) and in vitro rates of telokin
phosphorylation and to evaluate the possible effects of sequential
phosphorylation by different kinases. The in vivo site(s) of
phosphorylation of telokin were determined in rabbit smooth
muscles of longitudinal ileum and portal vein. Following
stimulation of ileum with forskolin (20 WM) the serine at position
13 was the only amino acid to exhibit increased phosphorylation.
Rabbit portal vein telokin was phosphorylated on both Ser-13
and -19 as a result of forskolin and GTPQS stimulation in
vivo. Point mutation of Ser-13 (to Ala or Asp) abolished in vitro
phosphorylation by cyclic nucleotide-dependent protein
kinases. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The major mechanism of activating smooth muscle contrac-
tion is through changes in [Ca2]i and the consequent phos-
phorylation of the regulatory myosin light chain (MLC20) by
the Ca2-calmodulin dependent myosin light chain kinase
(MLCK) [1,2]. MLC20 phosphorylation and contractile force
can also be increased by ‘Ca2 sensitization’ through a G-
protein coupled, Ca2 independent inhibition of smooth
muscle myosin phosphatase [3]. Phosphorylation of site A of
MLCK by calmodulin-dependent protein kinase II (CaMKII)
in vivo can reduce MLCK’s a⁄nity for Ca2-calmodulin and
leads to ‘Ca2-desensitization’ [4]. Ca2-desensitization is
manifested as a decline in MLC20 phosphorylation and force
in the absence of proportional, or any, decline in [Ca2] [5].
Another physiologically signi¢cant pathway of Ca2-desensi-
tization is mediated by the activation of cyclic nucleotide-de-
pendent protein kinases.
Several hormones and clinically administered nitrovasodila-
tors (such as atrial natriuretic peptide, endothelium-derived
relaxing factor (nitric oxide), and exogenous vasodilators) ex-
ert their actions to widen vessels and inhibit vasoconstriction
through activation of smooth muscle guanylate cyclase to el-
evate cGMP levels (for a review see [6^8]). One of the e¡ects
of elevated intracellular cGMP is the reduction of [Ca2]i. The
mechanisms by which cGMP-dependent protein kinase (PKG)
and smooth muscle relaxants that increase intracellular cGMP
lower intracellular Ca2 are numerous and have been well
characterized [8]. However, elevated intracellular [cGMP],
presumably through the activation of PKG, or cAMP-depen-
dent protein kinase (PKA), can also cause Ca2 desensitiza-
tion. This can be induced experimentally by treatment of per-
meabilized smooth muscle with 8-Br-cGMP at ¢xed [Ca2],
reversing G-protein coupled Ca2-sensitization and accelerat-
ing relaxation and dephosphorylation of MLC20 at constant
[Ca2] [9]. Importantly, the e¡ect is mimicked by the addition
of exogenous PKG or PKA to permeabilized smooth muscle
[10]. The mechanism of the Ca2-desensitizing e¡ect of cAMP
and cGMP is not known; however, telokin was identi¢ed as
the major cytosolic protein phosphorylated under the in£u-
ence of 8-Br-cGMP and was proposed to induce Ca2-desen-
sitization in smooth muscle by up-regulating the relaxant ef-
fects of myosin light chain phosphatase activity [11].
Indeed, the addition of recombinant telokin to permeabi-
lized smooth muscles produces a profound relaxation and
decrease in MLC20 phosphorylation of Ca2-induced contrac-
tions [11]. Telokin, also known as kinase-related protein
(KRP), is an abundant, small acidic protein (17 kDa) that
was ¢rst identi¢ed by Hartshorne and colleagues [12] and
found to be identical to the carboxy terminus of MLCK
[13]. Telokin and MLCK are expressed independently from
two di¡erent promoters; telokin expression is through the
action of serum response factor [13] and a smooth muscle
speci¢c promoter located in an intron of the MLCK gene
[14]. The protein is only expressed in certain smooth muscles,
with the highest levels of expression found in phasic smooth
muscle [15] with little if any expression in tonic muscle [11,13].
Telokin binds to the S1^S2 region of myosin through the
acidic carboxyl terminus [15] and prevents myosin from
adopting the 10 S conformation [16]. Telokin stabilizes un-
phosphorylated myosin ¢laments in vitro against ATP-depen-
dent depolymerization [15], and modulates, in vitro, the oli-
gomerization of MLCK [17] as well as the phosphorylation
rate of myosin by the competitive inhibition of MLCK [18]
[19]. It has been suggested that telokin’s physiological func-
tion is mediated through its stabilization of myosin ¢laments;
however, tonic smooth muscles with little or no telokin have
normal arrays of myosin ¢laments [20] indicating that telokin
is not necessary for in vivo ¢lament stability.
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The crystal structure of telokin shows that the protein con-
sists of an immunoglobulin-like L-barrel and a £exible amino
terminal 35 amino acids [21]. The unstructured amino termi-
nus is serine and threonine rich and contains substrate recog-
nition sequences for a variety of kinases, including cyclic nu-
cleotide-dependent protein kinases (PKA and PKG), mitogen-
activated protein kinase (MAPK), CaMKII, [11,12,22] and
MLCK [18]. To gain a better understanding of the role of
phosphorylated telokin in smooth muscle, we mapped its in
vivo phosphorylation site(s) in stimulated ileum and portal
vein and investigated the role of phosphorylation on its relax-
ant activity. Our results suggest that telokin is phosphorylated
on a single residue (Ser-13) in ileum and on two residues (Ser-
13 and Ser-19) in portal vein.
2. Materials and methods
2.1. Materials
Recombinant p42MAPK was puri¢ed from Escherichia coli strain
BL21(DE3)[pET-MK][23]. The constitutively active S218D/S222D
MEK1 was a gift from Dr. Andrew Cattling (Department of Micro-
biology, University of Virginia, VA, USA). Rabbit telokin cDNA in a
pET expression plasmid was a gift of Dr. Paul Herring (Indiana
University, IA, USA). cAMP-dependent protein kinase catalytic sub-
unit (PKAc) was purchased from Calbiochem Inc. (San Diego, CA,
USA).
2.2. Preparation of 32P-phosphorylated recombinant telokin
Recombinant rabbit telokin was prepared as previously described
[11]. The recombinant protein was phosphorylated for 2 h at 25‡C to
a stoichiometry of 1 mol/mol in a 5-ml reaction containing 3 mg of
recombinant telokin, 25 mM HEPES, pH 7.2, 5 mM MgCl2, 0.1 mM
DTT, 0.3 mM [Q-32P]ATP (250 cpm/nmol) and either 3 Wg PKAc or
3Wg PKG. Excess [Q-32P]ATP was removed by dialysis against 25 mM
HEPES, pH 7.2, 0.1 mM EDTA, 1 mM DTT, 0.1 mM phenylmeth-
ylsulfonyl £uoride (PMSF), and 1 mM benzamidine.
2.3. Phosphorylation site analysis of 32P-recombinant telokin
32P-Telokin samples (0.5 mg) from in vitro phosphorylation reac-
tions were incubated at 37‡C for 15 h with lysyl endopeptidase (20 Wg/
ml). The digests were acidi¢ed by addition of tri£uoroacetic acid
(TFA) and applied to a reverse phase column (Waters Nova-Pak
C18, 3.9U150 mm) that had been equilibrated in 0.1% TFA (Bu¡er
A). The £ow rate was maintained at 1 ml/min. The column was
washed for 10 min with Bu¡er A before peptides were eluted with a
linear gradient of acetonitrile (0^80% in 80 min) in bu¡er A. Fractions
(1 ml) were collected, and peptides containing 32P were identi¢ed by
measuring Cerenkov radiation. Those fractions were pooled and
evaporated to dryness before the peptides were immobilized to Im-
mobilon membrane (Millipore) following the manufacturer’s instruc-
tions. The 32P-labeled peptides generated by phosphorylating re-
combinant telokin with [Q-32P]ATP were identi¢ed with a vapor
phase amino acid sequencer (Applied Biosystems, Procise 494). Phos-
phorylated residues within phosphopeptides were located by determin-
ing the cycles in which 32P was released when samples were subjected
to sequential Edman degradation under conditions that optimize re-
covery of 32P [24].
As an alternative, solid phase mixed peptide sequencing [25] with
32P release was used to establish the precise 32P-labeled site. Phos-
phorylated recombinant telokin was run on SDS^PAGE gels and
transferred to PVM membrane. The membranes were stained with
amido black and then exposed to ¢lm. The autoradiograms were
overlaid onto the PVM membrane to align the phosphoprotein signal
with the distinct amido black staining protein. The protein band was
excised from the membrane with a razor, and after treatment with
cyanogen bromide, the membrane piece was placed directly into a 494
Procise sequencing cartridge (Perkin-Elmer) for mixed peptide se-
quencing. Phosphorylated residues were identi¢ed by sequential Ed-
man degradation as described above.
2.4. In vivo phosphorylation site determination of telokin
The portal vein and the longitudinal muscle of the ileum were
removed from rabbits anesthetized by halothane and exsanguinated
according to approved animal protocols. Two groups of intact
smooth muscle strips (250 WmU2 mm) were incubated in HEPES-
bu¡ered Krebs solution in the presence of [32P]PO334 (5 mCi/ml) at
room temperature for 1 h, followed by the addition of forskolin (50
WM) to one group. After 15 min, both control and agonist-treated
groups were £ash frozen in liquid N2 and then homogenized in lysis
bu¡er (20 mM Tris^HCl, pH 7.5, 250 mM sucrose, 5 mM EDTA,
1 mM DTT, 10 nM microcystin, 2 Wg/ml aprotinin, 2 Wg/ml leupeptin,
and 0.1 mM PMSF). After a 45-min centrifugation at 100 000Ug, the
soluble component was fractionated by anion exchange chromatogra-
phy (MiniQ; 2.3U3 cm) on a SMART-System FPLC (Pharmacia). A
linear gradient of 0^1 M NaCl in 20 mM Tris^HCl, pH 8.0, 0.1 mM
EDTA, 1 mM DTT at a £ow rate of 50 Wl/min over 30 min was
employed, and 50-Wl fractions were collected. Aliquots (10 Wl) of
each fraction were run on SDS^PAGE gels and silver-stained. Telokin
containing fractions were identi¢ed by autoradiography and immuno-
blotting. The remaining volume (40 Wl) of telokin containing fractions
was treated with endolysylpeptidase, and the phosphopeptides gener-
ated were puri¢ed over reverse phase HPLC. Phosphorylated residues
were identi¢ed by sequential Edman as described above.
In another series of experiments, ileum muscle and portal vein strips
were permeabilized with L-escin based on published protocols [9] and
then incubated in a Ca2-free solution containing 10 mM EGTA and
0.5 mM [Q-32P]ATP (NEN Life Science Products). Strips were incu-
bated in pCa 6.3, ileum, and pCa 6.5, with 10WM microcystin, portal
vein, with or without added 50 WM GTPQS. Similar procedures as
outlined above were used to isolate 32P-labeled telokin and identify
the in vivo site(s) of phosphorylation.
2.5. Preparation and treatment of Triton X-100-permeabilized smooth
muscle ileum
Details of methods and solutions have been described elsewhere
[11]. For storage, small strips of rabbit ileum were permeabilized for
15 min with 0.1% Triton X-100 in a Ca2-free solution containing
1 mM EGTA (G1), immersed in a relaxing solution with 50% glycer-
ol, and stored at 320‡C for up to 4 weeks. Stored strips were washed
three times with G1 solution prior to use. The strips were connected
to an isometric force transducer (AM801), and mounted in a well on a
bubble plate. After permeabilization, unless noted otherwise, all ex-
periments were carried out in the presence of 1 WM calmodulin at
room temperature. The maximal responses evoked by calcium (pCa
4.5) were assessed and then the strips were washed three times in G1.
The strips were incubated in pCa 6.3 to obtain a sub-maximal con-
traction prior to the addition of exogenous telokin. Telokin or phos-
phorylated telokin (20 WM) in 30 mM PIPES, 5 mM magnesium
methane sulfonate, 165 mM potassium methane sulfonate, pH 7.0
was added at the plateau of pCa tension and the magnitude and
rate of relaxation measured.
2.6. Telokin phosphorylation by PKA and MAPK
Phosphorylation of telokin and telokin mutants was performed at
23‡C in 25 mM HEPES, pH 7.2, 1 mM MgCl2, 0.1 mM DTT with 0.2
mM [Q-32P]ATP and either 3 Wg PKA catalytic subunit or 3 Wg acti-
vated MAPK. MAPK was activated by phosphorylation with re-
combinant S218D/S222D MEK1 as described previously [23]. The
stoichiometry of telokin phosphorylation was measured by terminat-
ing the kinase reactions with 25% TCA after pre-determined time
intervals. The radioactivity incorporated into the precipitated proteins
was assessed by Cerenkov counting.
3. Results
3.1. Telokin phosphorylation
In vitro phosphorylation of recombinant telokin protein by
both PKG- and PKA-catalyzed phosphate incorporation ex-
clusively onto serine as determined by phospho-amino acid
analysis (data not shown). To determine the precise amino
acid residue that was phosphorylated, 1 nmol of the 32P-la-
beled protein was digested overnight with endolysylpeptidase.
Reverse phase phosphopeptide mapping of the digest showed
that s 95% of the total radioactivity present in the protein
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was incorporated into a single peptide (Fig. 1). After further
puri¢cation of the phosphopeptide over capillary reverse
phase HPLC, the amino acid sequence was determined by
Edman sequencing. The puri¢ed phosphopeptide contained
a single amino acid sequence, SSTGSPTSPLTAE. Solid phase
sequencing, in which radioactivity was collected after each
cycle, suggested that the incorporated 32P was split between
the ¢rst and second cycle. Subsequently, solid phase-mixed
peptide sequencing [25] with detection of 32P release was
used to unambigously establish the in vitro PKA/PKG site
as Ser-13 (Fig. 1).
In ileum strips, the in vivo phosphorylation site(s) of telokin
were determined by 32P-labeling in HEPES-bu¡ered Krebs
solution followed by treatment with either DMSO (control),
GTPQS, or forskolin. Forskolin induced protein phosphoryla-
tion of Ser-13 (Fig. 2). There was also a signi¢cant, but lesser,
amount of 32P incorporation onto this same site in control
ileum, indicating a basal level of phosphorylation on Ser-13.
GTPQS treatment did not generate results di¡erent from that
induced by the other treatments. We were unable to identify
32P incorporation on either of the two putative MAPK sites,
Ser-16 or Ser-19, following stimulation of ileum with GTPQS
or forskolin.
The in vivo phosphorylation site(s) of telokin were deter-
mined in a similar manner in portal vein. In this case, an
increase in phosphorylation of the Ser-13 site was evident
following stimulation with either GTPQS or forskolin. Minor
phosphorylation of the Ser-19 site was observed with forsko-
lin treatment. Phosphorylation of the Ser-19 site was most
pronounced when GTPQS was used to stimulate portal vein
in the presence of microcystin (Fig. 3). There also appeared to
be a small amount of basal phosphorylation of these two sites.
3.2. E¡ects of telokin and phospho-telokin on smooth muscle
contraction
To determine whether in vitro phosphorylation of Ser-13
Fig. 1. A: Resolution of 32P-phosphopeptides generated by lysyl endopeptidase digestions of recombinant telokin phosphorylated in vitro by
PKA. Telokin was incubated at 25‡C for 2 h. The 32P-labeled proteins were then digested with lysyl endopeptidase, and then the resulting pep-
tides were applied to a reverse phase column and eluted with an increasing gradient of acetonitrile (dashed line). The results show the absor-
bance pro¢le at 214 nm (solid line), and the amount of 32P recovered in fractions (1 ml) (open symbols). B: Identi¢cation of the in vitro site(s)
of phosphorylation in puri¢ed phosphopeptides obtained from endolysylpeptidase-digested telokin phosphorylated by PKA. Peptides were
coupled to Sequelon AA disks and phosphorylated residues were identi¢ed by sequential Edman degradation. The amount of 32P released in
each cycle was quantitated by Cerenkov counting. C: Identi¢cation by mixed peptide sequencing of sites in telokin phosphorylated in vitro by
PKA. Recombinant telokin was incubated for 2 h with [Q-32P]ATP and either PKA or PKG prior to mixed peptide sequencing with 32P release
to establish the 32P-labeled site(s) on the protein. Telokin was excised from a PVM membrane with a razor, and after treatment with cyanogen
bromide, the membrane piece was placed into a 494 Procise sequencing cartridge (Perkin-Elmer) for mixed peptide sequencing. The results rep-
resent the amount of 32P released in each cycle when the peptides were subjected to sequential Edman degradation.
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a¡ects the ability of telokin to relax smooth muscle, we
treated Triton X-100-permeabilized smooth muscle with re-
combinant telokin and phospho-telokin (20 WM). There was
no di¡erence in the rate or extent of relaxation obtained from
the addition of telokin when compared with the addition of
phosphorylated telokin (data not shown).
3.3. In vitro phosphorylation of telokin mutants by PKA and
MAPK
With evidence showing phosphorylation of both Ser-13 and
Ser-19 in vivo, telokin mutants were created in order to assess
phosphorylation potential in vitro. Wild-type and the S19A
mutant were good substrates for PKAc in vitro with no di¡er-
ences in the overall stoichiometry of phosphorylation (reach-
ing a stoichiometry of V1.0 mol of phosphate/mol of pro-
tein), as shown in Fig. 4A. The rate of phosphorylation of the
S19A mutant was faster (reaching a stoichiometry of V0.8
mol of phosphate/mol of protein in 10 min) than that of the
wild-type telokin (reaching a stoichiometry of V0.8 mol of
phosphate/mol of protein in 40 min). The S13A and S13D
mutants were not phosphorylated to any signi¢cant extent
by PKAc; the maximal phosphorylation levels ranged from
0.05 to 0.1 mol/mol.
There were no di¡erences in the rate or overall stoichiom-
etry of phosphorylation among any of the recombinant telo-
kin species when phosphorylated by MAPK (Fig. 4B). MAPK
Fig. 2. Identi¢cation of sites in rabbit ileum longitudinal smooth
muscle telokin phosphorylated after treatment with (A) DMSO; (B)
forskolin; or (C) GTPQS. Ileum smooth muscle strips were K-toxin-
permeabilized, except those used for the forskolin treatment, prior
to contraction in pCa 6.3 solution with 1 WM calmodulin. Samples
of telokin from control and stimulated 32P-labeled ileum were di-
gested with endolysylpeptidase. Phosphopeptides were resolved by
reverse phase HPLC, coupled to Sequelon AA disks, and subjected
to sequential Edman degradation. The results represent the amount
of 32P released in each cycle when the peptides were subjected to se-
quential Edman degradation.
Fig. 3. Identi¢cation of sites in rabbit portal vein telokin phosphor-
ylated after treatment with (A) DMSO; (B) forskolin; or (C)
GTPQS. Portal vein strips were permeabilized with L-escin (50 WM
for 30 min), except those used for the forskolin treatment, prior to
contraction in pCa 6.5 solution with 1WM calmodulin and 10 WM
microcystin. Forskolin-treated portal vein was contracted in pCa 6.5
solution without the addition of calmodulin or microcystin. Telokin
samples were prepared as in Fig. 2. The results represent the
amount of 32P released in each cycle when the peptides were sub-
jected to sequential Edman degradation.
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phosphorylated all telokin mutants to V1 mol of phosphate/
mol of protein by 120 min. Interestingly, the S19A mutant
was as good an in vitro substrate for MAPK as the wild-
type protein. Using sequential Edman degradation, we found
that the in vitro MAPK site present on wild-type telokin was
exclusively Ser-19; however, on the S19A mutant, the phos-
phorylation occurred exclusively on Ser-16 (data not shown).
These results suggest that the in vitro phosphorylation of
wild-type telokin by MAPK is preferred and exclusive to
Ser-19.
We also tested whether prior phosphorylation by PKAc
a¡ected the subsequent rate of phosphorylation by MAPK
(Fig. 4C). Wild-type telokin was incubated at 25‡C with PKA-
c+unlabeled ATP or PKAc alone. Telokin incubated with
PKAc+ATP was phosphorylated to a stoichiometry of ap-
proximately 0.8 mol/mol (V2 h), and excess PKA inhibitor
peptide (10 WM) was added to both reaction tubes. Activated
MAPK and [32QP]ATP was added, and the stoichiometry of
phosphorylation was determined. Pre-phosphorylation with
PKAc did not a¡ect the stoichiometry of phosphorylation
by MAPK. Phosphate incorporation onto both PKAc phos-
pho-telokin and non-phosphorylated telokin reachedV1 mol/
mol within 120 min.
4. Discussion
The phosphorylation of telokin in situ has been reported
previously [11,12,22]. Because telokin contains multiple con-
sensus phosphorylation sites for both cyclic nucleotide-depen-
dent protein kinases and MAPK, it was not clear which of the
phosphorylation sites was involved in the regulatory function.
Mass spectrometry results of rabbit ileum smooth muscle te-
lokin peptides eluted from two-dimensional gels showed pos-
sible phosphorylation of a proline-directed consensus site and
suggested phosphorylation of telokin by MAPK in vivo [11].
However, the resolved peptide, RKSSTGSPTSPLTAER, con-
tained consensus sites for both cyclic nucleotide-dependent
protein kinases (underlined) and MAPK (bold). An additional
mass of V80 kDa associated with this peptide could result
from the phosphorylation of either MAPK or cyclic nucleo-
tide-dependent protein kinase sites. The goal of this study was
to determine the precise phosphorylation sites on telokin that
result from stimulation.
In vitro phosphorylation by cyclic nucleotide-dependent
protein kinases results in phosphorylation solely at Ser-13,
and if this site is replaced by a non-phosphorylatable residue
(SCA/D mutant), phosphorylation is inhibited. By using sol-
Fig. 4. Time course for the phosphorylation of recombinant telokin mutants, 0.1 mg wild-type (E), 13A (a), 13D (7), or 19A (O) by (A)
PKA catalytic subunit and (B) activated MAPK. A 250-Wl reaction mixture containing 25mM HEPES, pH 7.2, 200 WM ATP (250 cpm/nmol),
5 mM MgCl2, and 3 Wg of either PKA catalytic subunit or activated MAPK. The stoichiometry of phosphorylation was determined by remov-
ing 10-Wl aliquots of the reaction mixtures and measuring 32P incorporation into TCA-precipitated protein. C: The time courses of phosphory-
lation by MAPK for telokin pre-phosphorylated with PKA catalytic subunit (7) and unphosphorylated telokin (E) are shown. Wild-type telo-
kin was phosphorylated to stoichiometry with PKA catalytic subunit prior to the addition of activated MAPK. Data are means þ S.E.M., n = 4.
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id phase mixed peptide sequencing with 32P release, we estab-
lished the in vivo 32P-labeled site on the protein. Telokin is
phosphorylated solely at Ser-13 in intact ileum stimulated
with forskolin. We were unable to ¢nd evidence of in vivo
phosphate incorporation on either MAPK site, Ser-16 or
Ser-19, in forskolin or GTPQS-stimulated ileum. Interestingly,
there was 32P incorporation on Ser-19 in telokin isolated from
portal vein; phosphorylation of this site was more pro-
nounced when the muscle had been treated with microcystin,
a potent phosphatase inhibitor, plus added agonists. These
results suggest that phosphorylation of the Ser-19 site may
be strongly regulated by the action of protein phosphatases.
The functional signi¢cance of the Ser-19 site in the two di¡er-
ent muscles remains unclear.
We tested the hypothesis that phosphorylation of Ser-13
may alter the ability of Ser-19 to be phosphorylated by
MAPK. Ser-13 was phosphorylated to a 1 mol/mol stoichi-
ometry with PKA and then treated with MAPK. There was
no enhancement of phosphorylation at the MAPK sites when
the protein had been previously phosphorylated with PKA at
Ser-13, or alternatively, no enhancement of phosphorylation
at Ser-13 when a 19D telokin mutant was used (data not
shown). Furthermore, exogenous, activated MAPK (5 WM)
added to permeabilized ileum, had no relaxant e¡ect as seen
previously [26]. The importance of telokin phosphorylation by
MAPK remains to be elucidated. One possibility is that Ser-19
phosphorylation regulates potentiation of telokin-induced re-
laxation by cyclic nucleotides. Relaxation in permeabilized
ileum is super-potentiated by cyclic nucleotides in the presence
of exogenous 13D/19A telokin [27].
Thus, it appears that in vitro phosphorylation at Ser-13 is
not required for the Ca2-desensitizing action of telokin;
although, we cannot rule out the possibility that telokin phos-
phorylated in vitro was dephosphorylated when added to
smooth muscle. The thiophosphorylation of telokin was at-
tempted, but it labeled with very low stoichiometry. It is pos-
sible that the phosphorylation of additional protein(s) is re-
quired for full potentiation of telokin’s relaxant properties.
The concomitant reduction of the e¡ect of 8-Br-cGMP and
PKG with the loss of endogenous telokin from permeabilized
smooth muscle reported previously [11] may be a result of the
loss of both telokin and additional di¡usible proteins. We are
currently identifying by mixed peptide sequencing other small
molecular weight proteins that are phosphorylated in response
to cyclic nucleotide agonists and may have a cooperative role
in smooth muscle Ca2-desensitization.
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